PDF(Pubmed)
Abstract：
Optimal therapeutic and diagnostic efficacy is essential for healthcare\'s global mission of advancing oncologic drug development. Accurate diagnosis and detection are crucial prerequisites for effective risk stratification and personalized patient care in clinical oncology. A paradigm shift is emerging with the promise of multi-receptor-targeting compounds. While existing detection and staging methods have demonstrated some success, the traditional approach of monotherapy is being reevaluated to enhance therapeutic effectiveness. Heterodimeric site-specific agents are a versatile solution by targeting two distinct biomarkers with a single theranostic agent. This review describes the innovation of dual-targeting compounds, examining their design strategies, therapeutic implications, and the promising path they present for addressing complex diseases.
摘要：
最佳的治疗和诊断功效对于推进肿瘤药物开发的医疗保健全球使命至关重要。准确的诊断和检测是临床肿瘤学中有效的风险分层和个性化患者护理的关键前提。随着多受体靶向化合物的前景，范式转变正在出现。虽然现有的检测和分期方法已经证明了一些成功，正在重新评估传统的单一治疗方法，以提高治疗效果。异二聚体位点特异性药剂是通过用单一治疗诊断剂靶向两种不同的生物标志物的通用解决方案。本文综述了双靶向化合物的创新，检查他们的设计策略，治疗意义，以及他们提出的解决复杂疾病的有希望的途径。
